CN105031207A - Sugar-free pulse-activating decoction oral liquid and preparation method thereof - Google Patents
Sugar-free pulse-activating decoction oral liquid and preparation method thereof Download PDFInfo
- Publication number
- CN105031207A CN105031207A CN201510353909.XA CN201510353909A CN105031207A CN 105031207 A CN105031207 A CN 105031207A CN 201510353909 A CN201510353909 A CN 201510353909A CN 105031207 A CN105031207 A CN 105031207A
- Authority
- CN
- China
- Prior art keywords
- shengmai yin
- diluent
- sugarless type
- preparation
- yin koufuye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses sugar-free pulse-activating decoction oral liquid and a preparation method thereof. The preparation method comprises the following steps: (1) weighing red ginseng, radix ophiopogonis and schisandra chinensis, mixing, crushing into crude powder, adding alcohol with weight being 3-5 times of that of the crude powder into the crude powder, soaking for 24-48h, percolating, collecting 4000-5000ml the percolate, carrying out vacuum concentration till the volume of the percolate is 200-300ml, adding with water for diluting, uniformly stirring the diluent, adding with a pH regulator for adjusting the diluent till the pH is 6.5-8.0, and placing the diluent under temperature of 4-8 DEG C for refrigeration for 48-72h; and (b) placing the diluent after refrigeration at 4-8 DEG C, centrifuging for 20-30 min at the rotation speed of 10000-15000rpm, adding a preservative into the supernate obtained by centrifuging, then adding with water till the volume is 1000ml, regulating the pH to be 6.5-7.5 by using a pH regulator, adding with a buffer agent, stirring uniformly, canning, sealing, and sterilizing, and thus preparing the sugar-free pulse-activating decoction oral liquid. With the adoption of the preparation method disclosed by the invention, the filtering effect of the diluent is good, the filtering speed of the diluent is high, and the prepared sugar-free pulse-activating decoction oral liquid is good in mouthfeel and stability, and can be subjected to large-scale industrial production.
Description
Technical field
The present invention relates to pharmaceutical field, be specifically related to a kind of Sugarless type SHENGMAI YIN KOUFUYE and preparation method thereof.
Background technology
SHENGMAI YIN is a kind of listing traditional Chinese patent medicine for many years, it is by Radix Ginseng Rubra, Radix Ophiopogonis and the Fructus Schisandrae Chinensis pure Chinese medicine oral liquid through Hydrolysis kinetics, there is effect of Yiqi and vein recovery, YIN nourishing and the production of body fluid promoting, for QIYINLIANGXU, shortness of breath and palpitation, faint pulse spontaneous perspiration, current SHENGMAI YIN is used for the diseases such as treatment coronary heart diseases and angina pectoris, refractory heart failure and myocardial infarction clinical." Chinese Pharmacopoeia " version one in 2010 describes prescription and the method for making of SHENGMAI YIN, and concrete, the prescription of SHENGMAI YIN is as follows: Radix Ginseng Rubra 100g, Radix Ophiopogonis 200g, Fructus Schisandrae Chinensis 100g.The method for making of SHENGMAI YIN is as follows: Radix Ginseng Rubra, Radix Ophiopogonis and Fructus Schisandrae Chinensis powder are broken into coarse powder, uses 65% ethanol as solvent, carries out percolation after dipping 24h, collect percolate and be about 4500ml, be evaporated to about 250ml, let cool, the 400ml that adds water dilutes, and filters, and separately adds 60% syrup 300ml and appropriate antiseptic, and adjust ph is to prescribed limit, add water to 1000ml, stir evenly, leave standstill, filter, embedding, sterilizing, to obtain final product.But, adopt said method in actual production, prepare SHENGMAI YIN to find, percolate is after concentrating under reduced pressure, thin up, it is very difficult in filtration link, and filtration weak effect, to this, applicant once adopted and added different clarifier and autoclaved mode process, but effect is also undesirable, cause SHENGMAI YIN cannot carry out large-scale industrialization production.
Through investigation, the prescription of SHENGMAI YIN commercially available is at present divided into Radix Codonopsis side and two kinds, Radix Ginseng Rubra side, and these two kinds of SHENGMAI YIN are sugar-containing type, be specifically correctives with sucrose, but the easy moisture absorption of sucrose, and viscosity is large, not easily fill, and then cause SHENGMAI YIN less stable in storage process.Separately there are some researches show, after Wistar rat gives 6 weeks sucrose water, its body weight and serum triacylglycerol raise, the damage of pancreas, hepatic pathology is in increasing the weight of trend, and existing SHENGMAI YIN is mainly used in the patient with hyperlipemia, diabetes or coronary heart disease, because the lipid of patient itself and carbohydrate metabolism exist certain dysbolismus, therefore clinically patient to take course for the treatment of of SHENGMAI YIN longer, we can find out thus, and the sugary SHENGMAI YIN of long-term taking is unfavorable for the recovery of patient health.
Applicant learns through inspection information, describing in " preparation of Sugarless type SHENGMAI YIN KOUFUYE " literary composition that 17th volumes the 2nd in 1992 of Chinese periodical " CHINA JOURNAL OF CHINESE MATERIA MEDICA " are interim adopts water extraction method for refining to prepare Sugarless type SHENGMAI YIN, namely filtered through gauze lixiviating solution is adopted, filter in the filtrate obtained and also need to add clarifier with absorption suspended solids wherein, as can be seen here, the SHENGMAI YIN KOUFUYE of Sugarless type disclosed in this article also exists the problem filtering weak effect equally in preparation process, and the party is Radix Codonopsis side, ingredient and Radix Ginseng Rubra differ greatly, moreover, it adopts water extraction to refine, also completely different from the extracting method of Radix Ginseng Rubra side.
Summary of the invention
Primary and foremost purpose of the present invention is to provide a kind of good stability, take safe Sugarless type SHENGMAI YIN KOUFUYE.
For achieving the above object, the technical solution used in the present invention is: a kind of Sugarless type SHENGMAI YIN KOUFUYE, its raw materials comprises the component of following parts by weight: Radix Ginseng Rubra 95 ~ 105, Radix Ophiopogonis 190 ~ 210, Fructus Schisandrae Chinensis 95 ~ 105, antiseptic 0.5 ~ 3, buffer agent 0.03 ~ 0.54, surplus is water, and described each raw material components amounts in 1000 parts.
As further preferred version: the parts by weight of described each raw material are: Radix Ginseng Rubra 100, Radix Ophiopogonis 200, Fructus Schisandrae Chinensis 100, antiseptic 0.5 ~ 3, buffer agent 0.03 ~ 0.54, surplus is water.
Concrete scheme is, described antiseptic is one or more in benzoic acid and its esters, p-Hydroxybenzoate, sorbic acid and its esters; Described buffer agent is the compositions that citric acid and sodium citrate are formed by the mass ratio mixing of 1:6 ~ 18.Preferably, described antiseptic is sodium benzoate.
Another object of the present invention is to provide a kind of preparation method of Sugarless type SHENGMAI YIN KOUFUYE as above, and each raw material components needed for preparation amounts in 1000 parts, and its step is as follows:
A) Radix Ginseng Rubra, Radix Ophiopogonis and Fructus Schisandrae Chinensis is taken and mixed powder is broken into coarse powder, the ethanol of 3-5 times of quality is added in coarse powder, soak 24-48h, percolation, collect 4000-5000ml percolate, be evaporated to about 200-300ml, thin up, diluent stirred evenly and adds pH adjusting agent to be adjusted to pH value be 6.5-8.0, being then placed in cold preservation 48-72h under 4-8 DEG C of condition;
B) diluent after cold preservation is placed under 4-8 DEG C of condition with the centrifugal 20-30min of the rotating speed of 10000-15000rpm, first adding preservative agent in the centrifugal supernatant obtained, add water to 1000ml again, then use pH adjusting agent adjust ph to 6.5-7.5, add buffer agent again, embedding afterwards, sterilizing, to obtain final product.
Concrete scheme is, adopt in described step a to be mass percent be 65% ethanol.
SHENGMAI YIN disclosed by the invention is Sugarless type, can effectively improve the safety suffering from patient's life-time service such as diabetes, applied range when it uses.For the preparation method of SHENGMAI YIN, the preparation method of existing disclosed sugar-containing type and Sugarless type SHENGMAI YIN be all by thin up after diluent directly carry out filtrations and process, not only filter difficulty, and filtration weak effect, by comparison, preparation method disclosed by the invention first the pH value of the diluent after thin up is adjusted to 6.5-8.0, that is to say and diluent is adjusted to alkalescence by acidity, so not only can reduce the hydrolysis rate of effective active composition in diluent, and greatly can promote the filter effect of diluent, concrete, the present invention adopts the mode of low-temperature centrifugation to filter diluent, through verification experimental verification, said method disclosed by the invention is adopted not only to make the good filtration effect of diluent, and the rate of filtration is fast, effectively improve the preparation efficiency of SHENGMAI YIN, the more important thing is, the SHENGMAI YIN prepared not only mouthfeel is good, and stability is very good, be convenient to store, therefore there is good market prospect, large-scale industrialization production can be carried out.In addition, after testing, compared with prior art, adopt preparation method disclosed by the invention also effectively to improve the average content of the effective ingredient ginsenoside in SHENGMAI YIN, and then effectively improve the drug effect of SHENGMAI YIN.
As further preferred version: described step a is the mass percent adding 4 times of quality in coarse powder is the ethanol of 65%, soak 36h, percolation, collect 4500ml percolate, be evaporated to about 250ml, thin up, stirs evenly diluent and adds pH adjusting agent to be adjusted to pH value be 7.0, is then placed in cold preservation 72h under 4-8 DEG C of condition; Diluent after cold preservation is placed in the centrifugal 30min of the rotating speed of 10000-15000rpm under 4-8 DEG C of condition by described step b, first adding preservative agent in the centrifugal supernatant obtained, then adds water to 1000ml, then pH adjusting agent adjust ph to 7.0 is used, add buffer agent again, afterwards embedding, sterilizing.Concrete, described pH adjusting agent is one or more in sodium hydroxide, sodium dihydrogen phosphate-sodium hydrogen phosphate buffer, tartaric acid-sodium tartrate buffer, citric acid-sodium citrate buffer, Acetic acid-sodium acetate buffer.
Accompanying drawing explanation
Fig. 1 is the thin-layer chromatogram of Radix Ginseng Rubra in SHENGMAI YIN KOUFUYE;
Fig. 2 is the thin-layer chromatogram of Radix Ophiopogonis in SHENGMAI YIN KOUFUYE;
Fig. 3 is the thin-layer chromatogram of Fructus Schisandrae Chinensis in SHENGMAI YIN KOUFUYE;
Wherein, the D in Fig. 1 is panoxadiol and panaxatriol's reference substance mixture; D in Fig. 2 is control medicinal material Radix Ophiopogonis; D in Fig. 3
1for schisandrin reference substance; D in Fig. 3
2for Fructus Schisandrae Chinensis control medicinal material; In Fig. 1-3 1 is Sugarless type SHENGMAI YIN KOUFUYE of the present invention; In Fig. 1-3 2 is the SHENGMAI YIN KOUFUYE of prior art.
Detailed description of the invention
Below in conjunction with embodiment 1-4, technical scheme disclosed by the invention is further described:
Embodiment 1: the preparation of Sugarless type SHENGMAI YIN KOUFUYE of the present invention
A) 95g Radix Ginseng Rubra, 190g Radix Ophiopogonis, 95g Fructus Schisandrae Chinensis is taken, these three kinds of medical material mixed powders are broken into coarse powder, 65% ethanol of 3 times of quality is added in coarse powder, soak 24h, percolation, collect 4000ml percolate, be evaporated to about 200ml, thin up, stirs evenly diluent and adds sodium dihydrogen phosphate-sodium hydrogen phosphate buffer to be adjusted to pH value be 6.5, is then placed in cold preservation 48h under 4 DEG C of conditions;
B) diluent after cold preservation is placed under 4 DEG C of conditions with the centrifugal 20min of the rotating speed of 10000rpm, 3g sodium benzoate is first added in the centrifugal supernatant obtained, add water to 1000ml again, then sodium dihydrogen phosphate-sodium hydrogen phosphate buffer adjust ph to 6.5 is used, add citric acid 80mg again, sodium citrate 480mg, stirs evenly embedding, sterilizing, to obtain final product.
Embodiment 2: the preparation of Sugarless type SHENGMAI YIN KOUFUYE of the present invention
A) 105g Radix Ginseng Rubra, 210g Radix Ophiopogonis, 105g Fructus Schisandrae Chinensis is taken, these three kinds of medical material mixed powders are broken into coarse powder, 65% ethanol of 5 times of quality is added in coarse powder, soak 48h, percolation, collect 5000ml percolate, be evaporated to about 300ml, thin up, stirs evenly diluent and adds tartaric acid-sodium tartrate buffer to be adjusted to pH value be 8.0, is then placed in cold preservation 72h under 8 DEG C of conditions;
B) diluent after cold preservation is placed under 8 DEG C of conditions with the centrifugal 30min of the rotating speed of 15000rpm, 0.5 p-Hydroxybenzoate is first added in the centrifugal supernatant obtained, add water to 1000ml again, then tartaric acid-sodium tartrate buffer adjust ph to 7.5 is used, add citric acid 30mg again, sodium citrate 540mg, stirs evenly embedding, sterilizing, to obtain final product.
Embodiment 3: the preparation of Sugarless type SHENGMAI YIN KOUFUYE of the present invention
A) 100g Radix Ginseng Rubra, 200g Radix Ophiopogonis, 100g Fructus Schisandrae Chinensis is taken, these three kinds of medical material mixed powders are broken into coarse powder, 65% ethanol of 4 times of quality is added in coarse powder, soak 36h, percolation, collect 4500ml percolate, be evaporated to about 250ml, thin up, stirs evenly diluent and adds Acetic acid-sodium acetate buffer to be adjusted to pH value be 7.0, is then placed in cold preservation 60h under 6 DEG C of conditions;
B) diluent after cold preservation is placed under 6 DEG C of conditions with the centrifugal 25min of the rotating speed of 12000rpm, 4g sodium benzoate is first added in the centrifugal supernatant obtained, add water to 1000ml again, then Acetic acid-sodium acetate buffer adjust ph to 7.0 is used, add citric acid 42mg again, sodium citrate 530mg, stirs evenly embedding, sterilizing, to obtain final product.
Embodiment 4: the physicochemical property of the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art is checked
Take 100g Radix Ginseng Rubra, 200g Radix Ophiopogonis, 100g Fructus Schisandrae Chinensis, the SHENGMAI YIN KOUFUYE of prior art is prepared by technique under version " Chinese Pharmacopoeia " SHENGMAI YIN item in 2010, the Sugarless type SHENGMAI YIN KOUFUYE itself and embodiments of the invention 3 prepared carries out the inspection of following index respectively, and result is as follows:
[character]
Sugarless type SHENGMAI YIN KOUFUYE of the present invention is the supernatant liquid of rufous, and gas is fragrant, sour in the mouth, micro-hardship; The SHENGMAI YIN KOUFUYE of prior art is the supernatant liquid of rufous, and gas is fragrant, sweet and sour, micro-hardship.
[TLC distinguish]
(1) TLC distinguish of Radix Ginseng Rubra gets each 20ml of SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art respectively, detect by the standard method of prior art, result as shown in Figure 1, as can be seen from accompanying drawing 1, all aobvious identical fluorescence speckle on the position that Sugarless type SHENGMAI YIN KOUFUYE of the present invention is corresponding with reference substance chromatograph with the SHENGMAI YIN KOUFUYE of prior art.
(2) TLC distinguish of Radix Ophiopogonis gets each 10ml of SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art respectively, detect by the standard method of prior art, result as shown in Figure 2, as can be seen from accompanying drawing 2, all aobvious identical principal spot on the position that Sugarless type SHENGMAI YIN KOUFUYE of the present invention is corresponding with reference substance chromatograph with the SHENGMAI YIN KOUFUYE of prior art.
(3) TLC distinguish of Fructus Schisandrae Chinensis gets each 10ml of SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art respectively, detect by the standard method of prior art, result as shown in Figure 3, as can be seen from accompanying drawing 3, all aobvious identical fluorescence speckle on the position that Sugarless type SHENGMAI YIN KOUFUYE of the present invention is corresponding with reference substance chromatograph with the SHENGMAI YIN KOUFUYE of prior art.
[inspection]
(1) relative density measures by the standard method of prior art and learns, the relative density of the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art is respectively 1.04,1.12.
(2) pH value measures by the standard method of prior art and learns, the pH value of the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art is respectively 6.01,5.07.
[assay]
Measure by the standard method of prior art, measure the Fructus Schisandrae Chinensis (in schisandrin) contained in the every 10ml of SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art and be 1.14mg.
Above assay shows, the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art is all qualified, and except relative density, both other indexs are without obvious difference.
Embodiment 5: the active component ginsenoside Rg in the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art
1the comparison of content
Ginsenoside Rg
1be one of principle active component of ginsenoside, there is natural anti-oxidation effect.Research shows, severe ischemic acute stage excite myocardial tissue can produce a large amount of VEGF and HIF-1 α, thus shields to ischemic myocardium, ginsenoside Rg
1stimulate the angiogenesis in myocardial infarction district and Doppler flow mapping to set up by the expression of both increases.Scholar is had to demonstrate ginsenoside Rg by fluorescence analysis
1by reducing reactive oxygen species (antioxidation), [Ca in T suppression cell
2 +] level to be to maintain the oxidative damage of intracellular calcium homeostasis protection rat heart muscle anoxia _ reoxygenation.Result of study is pointed out, ginsenoside Rg
1have protective effect to rat acute ischemic myocardial, its Protective effects shows: ginsenoside Rg on the one hand
1can promote the angiogenesis of Model Rats with Acute Myocardial Ischemia cardiac muscle, its molecular mechanism may be act on VEGFR1, VEGFR2 by activating VEGF, is realized by Akt and NO signal transduction pathway; On the other hand, the vigor of rat blood serum SOD and GSH-Px can be increased, reduce the content of MDA, played the protective effect to ischemic myocardium by antioxidation.
Ginsenoside Rg
1have the effect of expansion basilar artary, its mechanism of action is comparatively complicated.Both by being subject to actuated Ca
2+ca in passage suppresses
2+release, again by voltage-dependent Ca
2+passage suppresses outer Ca
2+interior stream is relevant, and its effect can mediate by endotheliocyte.Ginsenoside Rg
1the generation of lipid of mice and lipid peroxide can be reduced.Research shows ginsenoside Rg
1the generation being used for suppressing hepatic glucose in HepG2 cell of Rg is suppressed by the activation of AMP activated protein kinase (AMPK).Therefore, the present invention is with ginsenoside Rg
1for evaluation index, the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art is compared.
One, HPLC measures ginsenoside Rg
1methodological investigation
1, the preparation of test sample solution is treated
Accurate absorption SHENGMAI YIN KOUFUYE 10ml, put in separatory funnel, with water saturated 20ml n-butanol extraction 4 times (each 20ml), leave standstill, divide and get n-butanol layer, wash twice (each 40ml) with 40ml ammonia solution, get n-butanol layer, reclaim n-butyl alcohol to dry, residue adds 5ml water dissolution, by D101 macroporous resin column (20g, internal diameter 1.5cm) on, first use 10% ethanol elution of 100ml, discard eluent, use 70% ethanol elution of 100ml again, collect eluent, evaporate to dryness, residue adds 5ml methanol makes dissolving, filter (0.22um film), be and treat test sample solution.
2, the preparation of reference substance solution
Precision takes ginsenoside Rg
1reference substance, puts in 10ml measuring bottle, adds methanol and makes dissolving and be diluted to scale, shake up, and accurate absorption 5ml, put in 10ml measuring bottle, add methanol and make dissolving and be diluted to scale, shake up, filter, product solution in contrast, concentration is 0.539mg/ml.
3, the selection of chromatographic condition
Chromatographic column is WatersSunFireC18 post (particle diameter 5 μm, size 4.6mm × 250mm); Take acetonitrile as mobile phase A, water is Mobile phase B, carries out gradient elution by the regulation in table 1; Column temperature is 30 DEG C, and determined wavelength is 250nm, and flow velocity is 1.0ml/min.
Table 1
4, repeatability
The accurate reference substance solution (concentration is 0.539mg/ml) drawn 10 μ l steps 2 and obtain, repeat sample introduction 6 times, measure its peak area value, result is as shown in table 2 below, therefrom can find out that RSD is 1.86% (RSD < 2.0%), repeatability better.
Table 2 ginsenoside Rg
1replica test result
5, the preparation of standard curve and the investigation of linear relationship
Accurate absorption reference substance solution storing solution (concentration is 1.3475g/ml) 0.5ml, 1ml, 2ml, 4ml, 8ml, be placed in 10ml volumetric flask respectively, add methanol dilution to scale, shake up, measure peak area by above-mentioned chromatographic condition, take peak area as vertical coordinate, concentration is abscissa drawing standard curve, obtain equation of linear regression A=3092527C-87821.9, r=0.999775 (n=5).Result is as shown in table 3 below, as can be seen from the table reference substance solution in the scope of measured concentration 0.0674mg ~ 1.0780mg/ml with the linear relationship that peak area is good.
Table 3 ginsenoside Rg
1the range of linearity investigates result
6, stability test
Get SHENGMAI YIN KOUFUYE 10ml, make after test sample solution by the method for step 1, immediately in accurate absorption 10 μ l injection liquid chromatographies, measure its peak area, and at regular intervals, measure 1 time.Result is as shown in table 4 below, treats that test sample solution is basicly stable in 24h as can be seen from the table, RSD=1.35%.
The stability test result of test sample solution treated by table 4
Two, the detection of sample
Get each 10ml of SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art, make as stated above and treat test sample solution, then precision is drawn reference substance solution and is treated each 10 μ l of test sample solution respectively, injection liquid chromatography, measure, result is as shown in table 5 below, as can be seen from the table, and ginsenoside Rg in Sugarless type SHENGMAI YIN KOUFUYE of the present invention
1content apparently higher than the SHENGMAI YIN KOUFUYE of prior art.
Table 5 ginsenoside Rg
1the mensuration (mg/g) of content
Embodiment 6: the stability of the SHENGMAI YIN KOUFUYE of Sugarless type SHENGMAI YIN KOUFUYE of the present invention and prior art compares
Take 100g Radix Ginseng Rubra, 200g Radix Ophiopogonis, 100g Fructus Schisandrae Chinensis, the SHENGMAI YIN KOUFUYE of prior art is prepared by technique under version " Chinese Pharmacopoeia " SHENGMAI YIN item in 2010, it is 38-42 DEG C that Sugarless type SHENGMAI YIN KOUFUYE prepared by itself and embodiments of the invention 3 is placed in temperature respectively, humidity is under the condition of 70%-80%, observe the 0th, 1, 2, 3, the stability in June, result is as shown in table 6, as can be seen from the table, the quality of the SHENGMAI YIN KOUFUYE (namely having sugar-type) of Sugarless type SHENGMAI YIN KOUFUYE (i.e. Sugarless type) of the present invention and prior art all conforms with the regulations.
Claims (9)
1. a Sugarless type SHENGMAI YIN KOUFUYE, its raw materials comprises the component of following parts by weight: Radix Ginseng Rubra 95 ~ 105, Radix Ophiopogonis 190 ~ 210, Fructus Schisandrae Chinensis 95 ~ 105, antiseptic 0.5 ~ 3, buffer agent 0.03 ~ 0.54, surplus is water, and described each raw material components amounts in 1000 parts.
2. Sugarless type SHENGMAI YIN KOUFUYE according to claim 1, is characterized in that: the parts by weight of described each raw material are: Radix Ginseng Rubra 100, Radix Ophiopogonis 200, Fructus Schisandrae Chinensis 100, antiseptic 0.5 ~ 3, and buffer agent 0.03 ~ 0.54, surplus is water.
3. Sugarless type SHENGMAI YIN KOUFUYE according to claim 1, is characterized in that: described antiseptic is one or more in benzoic acid and its esters, p-Hydroxybenzoate, sorbic acid and its esters.
4. Sugarless type SHENGMAI YIN KOUFUYE according to claim 1, is characterized in that: described buffer agent is the compositions that citric acid and sodium citrate are formed by the mass ratio mixing of 1:6 ~ 18.
5. Sugarless type SHENGMAI YIN KOUFUYE according to claim 2, is characterized in that: described antiseptic is sodium benzoate.
6. a preparation method for the Sugarless type SHENGMAI YIN KOUFUYE according to any one of claim 1-5, each raw material components needed for preparation amounts in 1000 parts, and its step is as follows:
A) Radix Ginseng Rubra, Radix Ophiopogonis and Fructus Schisandrae Chinensis is taken and mixed powder is broken into coarse powder, the ethanol of 3-5 times of quality is added in coarse powder, soak 24-48h, percolation, collect 4000-5000ml percolate, be evaporated to about 200-300ml, thin up, diluent stirred evenly and adds pH adjusting agent to be adjusted to pH value be 6.5-8.0, being then placed in cold preservation 48-72h under 4-8 DEG C of condition;
B) diluent after cold preservation is placed under 4-8 DEG C of condition with the centrifugal 20-30min of the rotating speed of 10000-15000rpm, first adding preservative agent in the centrifugal supernatant obtained, add water to 1000ml again, then use pH adjusting agent adjust ph to 6.5-7.5, add buffer agent again, stir evenly embedding, sterilizing, to obtain final product.
7. the preparation method of Sugarless type SHENGMAI YIN KOUFUYE according to claim 6, it is characterized in that: described step a is the mass percent adding 4 times of quality in coarse powder is the ethanol of 65%, soak 36h, percolation, collect 4500ml percolate, be evaporated to about 250ml, thin up, diluent stirred evenly and adds pH adjusting agent to be adjusted to pH value be 7.0, being then placed in cold preservation 72h under 4 DEG C of conditions.
8. the preparation method of Sugarless type SHENGMAI YIN KOUFUYE according to claim 6, it is characterized in that: the diluent after cold preservation is placed under 4 DEG C of conditions with the centrifugal 30min of the rotating speed of 10000-15000rpm by described step b, first adding preservative agent in the centrifugal supernatant obtained, add water to 1000ml again, then pH adjusting agent adjust ph to 7.0 is used, add buffer agent again, stir evenly embedding, sterilizing.
9. Sugarless type SHENGMAI YIN KOUFUYE according to claim 6, is characterized in that: described pH adjusting agent is one or more in sodium hydroxide, sodium dihydrogen phosphate-sodium hydrogen phosphate buffer, tartaric acid-sodium tartrate buffer, citric acid-sodium citrate buffer, Acetic acid-sodium acetate buffer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353909.XA CN105031207A (en) | 2015-06-25 | 2015-06-25 | Sugar-free pulse-activating decoction oral liquid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510353909.XA CN105031207A (en) | 2015-06-25 | 2015-06-25 | Sugar-free pulse-activating decoction oral liquid and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105031207A true CN105031207A (en) | 2015-11-11 |
Family
ID=54438567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510353909.XA Pending CN105031207A (en) | 2015-06-25 | 2015-06-25 | Sugar-free pulse-activating decoction oral liquid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105031207A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898921A (en) * | 2017-11-23 | 2018-04-13 | 铜陵市棵松农业科技有限公司 | SHENGMAI YIN KOUFUYE and preparation method thereof |
| CN108158990A (en) * | 2018-03-07 | 2018-06-15 | 孙奉生 | The production technology of Pitavastatin Ca oral liquid |
| CN110384756A (en) * | 2019-08-23 | 2019-10-29 | 广州市香雪制药股份有限公司 | No cane sugar type SHENGMAI YIN KOUFUYE and preparation method thereof |
| CN112263643A (en) * | 2020-11-26 | 2021-01-26 | 太极集团·四川天诚制药有限公司 | Pulse activating beverage without sucrose and preservative and preparation method thereof |
| CN112451613A (en) * | 2020-12-16 | 2021-03-09 | 山东罗欣乐康制药有限公司 | Preparation method of traditional Chinese medicine oral liquid |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157162A (en) * | 1996-02-14 | 1997-08-20 | 雅安三九药业有限公司 | Pulse-engendering injection and preparation method thereof |
-
2015
- 2015-06-25 CN CN201510353909.XA patent/CN105031207A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1157162A (en) * | 1996-02-14 | 1997-08-20 | 雅安三九药业有限公司 | Pulse-engendering injection and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 侯惠欣: "生脉饮改进方的质量考察", 《江苏药学与临床研究》 * |
| 宋开仁: "漫谈生脉散", 《福建中医药》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898921A (en) * | 2017-11-23 | 2018-04-13 | 铜陵市棵松农业科技有限公司 | SHENGMAI YIN KOUFUYE and preparation method thereof |
| CN108158990A (en) * | 2018-03-07 | 2018-06-15 | 孙奉生 | The production technology of Pitavastatin Ca oral liquid |
| CN110384756A (en) * | 2019-08-23 | 2019-10-29 | 广州市香雪制药股份有限公司 | No cane sugar type SHENGMAI YIN KOUFUYE and preparation method thereof |
| CN112263643A (en) * | 2020-11-26 | 2021-01-26 | 太极集团·四川天诚制药有限公司 | Pulse activating beverage without sucrose and preservative and preparation method thereof |
| CN112451613A (en) * | 2020-12-16 | 2021-03-09 | 山东罗欣乐康制药有限公司 | Preparation method of traditional Chinese medicine oral liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105031207A (en) | Sugar-free pulse-activating decoction oral liquid and preparation method thereof | |
| TW201521754A (en) | Traditional chinese medicine composition, and preparation and application thereof | |
| TW201536306A (en) | Traditional chinese medicine composition, and preparation and application thereof | |
| CN101297864B (en) | Preparation of Xia sang ju formulation | |
| CN100422737C (en) | Preparation method of 'Xue Fu Zhu Yu' capsule and quality standard thereof | |
| JP5622222B2 (en) | Hypolipidemic composition and use thereof | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN108339000A (en) | A kind of panax species extract and its pharmaceutical composition and application | |
| CN100478001C (en) | Tribulus terrestris extraction and its preparation method and use | |
| CN102846704B (en) | A Leonurus japonicus injection, its preparation method, and method for detecting total alkaloids | |
| CN102258578B (en) | Lotus leaf total alkaloid extract and preparation method as well as application thereof | |
| CN101049355B (en) | Composition of medication prepared from safflower and leaves of hawthorn | |
| CN1923229B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and puerarin | |
| CN1923228B (en) | Pharmaceutical composition comprising notoginseng extract, Danshen extract and ligustrazine | |
| CN100563682C (en) | A kind of pharmaceutical composition of making by Folium Crataegi and Radix Rhodiolae and preparation method thereof | |
| CN106913717A (en) | The preparation method and purposes of a kind of Pu bring down a fever piece | |
| CN101428020A (en) | Freeze-dried powder preparation of kuh-seng native, preparation and detection method thereof | |
| CN105147664B (en) | Puerarin injection and preparation method | |
| CN100570357C (en) | The detection method of 'Sheng Mai ' powder | |
| CN105001202B (en) | A kind of Esomeprazole sodium compound and its pharmaceutical composition | |
| Chaurasia et al. | Evaluation and marker quantification of antidiabetic herbal tablets: SteviTab and AndroTab by HPLC method | |
| CN106913516A (en) | A kind of blue syrup in Pu ground and its production and use | |
| CN100516869C (en) | Chinese medicine lung soothing oral liquid preparation and its detection method | |
| CN107137443A (en) | A kind of composition for relieving fatigue, preparation method and applications | |
| CN106267122A (en) | A kind of Fructus Trichosanthis Ramulus Cinnamomi drop pill and quality determining method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151111 |
|
| RJ01 | Rejection of invention patent application after publication |